Follow-up at School-age of Children Who Participated in the Efficacy Study of Nitric Oxide for Premature Infants
Follow up at School-age of Children Participating in the Nitric Oxide Ventilatory Approach (NOVA) Study
2 other identifiers
interventional
160
1 country
1
Brief Summary
Our previous data demonstrated that premature infants treated with inhaled nitric oxide at birth had improved neurodevelopmental outcomes at two years corrected age. We now wish to determine whether this benefit continues through school age.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_3
Started May 2005
Shorter than P25 for phase_3
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2005
CompletedFirst Submitted
Initial submission to the registry
September 8, 2005
CompletedFirst Posted
Study publicly available on registry
September 9, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2006
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2006
CompletedJune 12, 2013
March 1, 2009
1.3 years
September 8, 2005
June 11, 2013
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Examine school-readiness at school-age in premature infants treated with iNO or placebo in the first week of life
4-7 years of age (between 2005-2006)
Secondary Outcomes (1)
Examine health status at early school-age
4-7 years of age (between 2005-2006)
Study Arms (2)
Inhaled nitric oxide
EXPERIMENTALPlacebo
PLACEBO COMPARATORInterventions
Eligibility Criteria
You may qualify if:
- Children who participated in NOVA study and are of school age
You may not qualify if:
- Children who participated in NOVA study but deceased post discharge
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Chicagolead
- Mallinckrodtcollaborator
Study Sites (1)
The University of Chicago, Comer Children's Hospital,
Chicago, Illinois, 60637, United States
Related Publications (1)
Patrianakos-Hoobler AI, Marks JD, Msall ME, Huo D, Schreiber MD. Safety and efficacy of inhaled nitric oxide treatment for premature infants with respiratory distress syndrome: follow-up evaluation at early school age. Acta Paediatr. 2011 Apr;100(4):524-8. doi: 10.1111/j.1651-2227.2010.02077.x. Epub 2010 Dec 1.
PMID: 21054515DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Michael D Schreiber, M.D.
University of Chicago
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 8, 2005
First Posted
September 9, 2005
Study Start
May 1, 2005
Primary Completion
September 1, 2006
Study Completion
September 1, 2006
Last Updated
June 12, 2013
Record last verified: 2009-03